DENTSPLY SIRONA Inc. (XRAY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 1.5B 3B 4.5B Q3 '21: 4.2B Q4 '21: 4.2B Q1 '22: 4.2B Q2 '22: 4.1B Q3 '22: 4B Q4 '22: 3.9B Q1 '23: 3.9B Q2 '23: 3.9B Q3 '23: 3.9B Q4 '23: 4B Q1 '24: 3.9B Q2 '24: 3.9B Q3 '24: 3.9B Q4 '24: 3.8B Q1 '25: 3.7B Q2 '25: 3.7B Q3 '25: 3.6B Q4 '25: 3.7B Q1 '26: 3.7B Q2 '26: 3.6B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 800M 1.6B 2.4B Q3 '21: 2.3B Q4 '21: 2.3B Q1 '22: 2.3B Q2 '22: 2.3B Q3 '22: 2.2B Q4 '22: 2.1B Q1 '23: 2.1B Q2 '23: 2.1B Q3 '23: 2.1B Q4 '23: 2.1B Q1 '24: 2.1B Q2 '24: 2B Q3 '24: 2B Q4 '24: 2B Q1 '25: 1.9B Q2 '25: 1.9B Q3 '25: 1.8B Q4 '25: 1.8B Q1 '26: 1.8B Q2 '26: 1.8B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-1.2B -800M -400M 0 400M 800M 1.2B Q3 '21: 577M Q4 '21: 608M Q1 '22: 555M Q2 '22: 520M Q3 '22: -830M Q4 '22: -937M Q1 '23: -1B Q2 '23: -1.1B Q3 '23: -93M Q4 '23: -85M Q1 '24: -41M Q2 '24: -71M Q3 '24: -297M Q4 '24: -879M Q1 '25: -858M Q2 '25: -1B Q3 '25: -792M Q4 '25: -422M Q1 '26: -520M Q2 '26: -310M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-1.2B -800M -400M 0 400M 800M 1.2B Q3 '21: 397M Q4 '21: 411M Q1 '22: 368M Q2 '22: 345M Q3 '22: -816M Q4 '22: -950M Q1 '23: -1B Q2 '23: -1B Q3 '23: -214M Q4 '23: -132M Q1 '24: -95M Q2 '24: -185M Q3 '24: -413M Q4 '24: -910M Q1 '25: -908M Q2 '25: -949M Q3 '25: -882M Q4 '25: -598M Q1 '26: -628M Q2 '26: -546M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 700M 1.4B 2.1B Q3 '21: 1.9B Q4 '21: 1.9B Q1 '22: 1.9B Q2 '22: 1.9B Q3 '22: 1.8B Q4 '22: 1.8B Q1 '23: 1.8B Q2 '23: 1.8B Q3 '23: 1.9B Q4 '23: 1.9B Q1 '24: 1.9B Q2 '24: 1.9B Q3 '24: 1.9B Q4 '24: 1.8B Q1 '25: 1.8B Q2 '25: 1.8B Q3 '25: 1.8B Q4 '25: 1.8B Q1 '26: 1.9B Q2 '26: 1.8B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

0 200M 400M 600M Q3 '21: 313M Q4 '21: 49M Q1 '22: 93M Q2 '22: 266M Q3 '22: 375M Q4 '22: 517M Q1 '23: 403M Q2 '23: 334M Q3 '23: 359M Q4 '23: 377M Q1 '24: 423M Q2 '24: 527M Q3 '24: 534M Q4 '24: 461M Q1 '25: 443M Q2 '25: 283M Q3 '25: 221M Q4 '25: 235M Q1 '26: 268M Q2 '26: 319M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-150M 0 150M 300M 450M Q3 '21: 185M Q4 '21: -93M Q1 '22: -63M Q2 '22: 105M Q3 '22: 217M Q4 '22: 368M Q1 '23: 259M Q2 '23: 198M Q3 '23: 218M Q4 '23: 228M Q1 '24: 279M Q2 '24: 364M Q3 '24: 365M Q4 '24: 281M Q1 '25: 278M Q2 '25: 138M Q3 '25: 80M Q4 '25: 104M Q1 '26: 104M Q2 '26: 143M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q1 '20: 220.9M Q2 '20: 218.7M Q3 '20: 219.2M Q1 '21: 219.9M Q2 '21: 220.7M Q3 '21: 220.5M Q1 '22: 217.8M Q2 '22: 215.3M Q3 '22: 214.9M Q1 '23: 214.5M Q2 '23: 213.1M Q3 '23: 211.8M Q1 '24: 208.5M Q2 '24: 205.6M Q3 '24: 201M Q1 '25: 199.8M Q2 '25: 199.3M Q3 '25: 199.5M Q1 '26: 199.9M Q2 '26: 200.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: 1.80 Q4 '21: 1.86 Q1 '22: 1.67 Q2 '22: 1.58 Q3 '22: -3.81 Q4 '22: -4.42 Q1 '23: -4.83 Q2 '23: -4.77 Q3 '23: -1.01 Q4 '23: -0.62 Q1 '24: -0.44 Q2 '24: -0.86 Q3 '24: -2.07 Q4 '24: -4.52 Q1 '25: -4.51 Q2 '25: -4.71 Q3 '25: -4.39 Q4 '25: -2.99 Q1 '26: -3.14 Q2 '26: -2.74 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.